Insider Selling: Tyme Technologies Inc (NASDAQ:TYME) Major Shareholder Sells 20,000 Shares of Stock

Tyme Technologies Inc (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $0.97, for a total value of $19,400.00. Following the transaction, the insider now directly owns 24,005,617 shares in the company, valued at $23,285,448.49. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Friday, March 20th, Michael Demurjian sold 7,071 shares of Tyme Technologies stock. The stock was sold at an average price of $1.03, for a total value of $7,283.13.
  • On Monday, March 16th, Michael Demurjian sold 4,904 shares of Tyme Technologies stock. The stock was sold at an average price of $1.03, for a total value of $5,051.12.
  • On Monday, February 10th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.34, for a total value of $26,800.00.
  • On Monday, January 27th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.52, for a total value of $30,400.00.
  • On Tuesday, January 21st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.90, for a total value of $38,000.00.
  • On Monday, January 13th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.64, for a total value of $32,800.00.
  • On Monday, January 6th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.47, for a total value of $29,400.00.
  • On Monday, December 30th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.07, for a total value of $21,400.00.

TYME stock traded up $0.11 during midday trading on Tuesday, hitting $1.08. 396,804 shares of the company’s stock were exchanged, compared to its average volume of 548,798. Tyme Technologies Inc has a 12-month low of $0.86 and a 12-month high of $2.13. The firm has a 50 day moving average price of $1.20 and a 200-day moving average price of $1.31. The stock has a market capitalization of $117.91 million, a price-to-earnings ratio of -4.50 and a beta of 0.54.

Tyme Technologies (NASDAQ:TYME) last posted its quarterly earnings data on Wednesday, February 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, sell-side analysts forecast that Tyme Technologies Inc will post -0.22 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new stake in shares of Tyme Technologies in the 3rd quarter valued at approximately $71,000. Barclays PLC increased its holdings in shares of Tyme Technologies by 102.1% in the 4th quarter. Barclays PLC now owns 59,040 shares of the company’s stock valued at $83,000 after acquiring an additional 29,821 shares during the last quarter. Citigroup Inc. increased its holdings in shares of Tyme Technologies by 72.2% in the 4th quarter. Citigroup Inc. now owns 23,556 shares of the company’s stock valued at $33,000 after acquiring an additional 9,873 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Tyme Technologies in the 4th quarter valued at approximately $25,000. Finally, UBS Group AG increased its holdings in shares of Tyme Technologies by 49.1% in the 4th quarter. UBS Group AG now owns 90,630 shares of the company’s stock valued at $127,000 after acquiring an additional 29,829 shares during the last quarter. Institutional investors own 11.76% of the company’s stock.

Several research firms have issued reports on TYME. Zacks Investment Research upgraded Tyme Technologies from a “sell” rating to a “hold” rating in a report on Wednesday, March 18th. HC Wainwright restated a “buy” rating and set a $9.50 price objective on shares of Tyme Technologies in a report on Thursday, February 6th.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Featured Story: What is the S&P/ASX 200 Index?

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.